The biologics market is expanding rapidly – with a compound annual growth rate of 15% predicted until 2027. But this new generation of drugs comes with unique challenges that require an innovative approach underpinned by extensive experience.
BioProduction by SEKISUI’s Kirsty Bellchambers and Aurore Laborie-Thompson share insights into what drug developers need to know about transferring their biologics processes to a CDMO partner.
Arriello’s Kate Coleman reviews the findings of new transatlantic research which charts biotechs’ evolving commercialisation strategies and regulatory preparations, and the realities they are experiencing.
SGS has announced the launch of Germany’s first commercial cell sorting service via fluorescent-activated cell sorting (FACS) for the biopharmaceutical industry.
Anne Dhulesia, partner, Sean Dyson, partner, and Guy Stephens, manager, L.E.K. Consulting, discuss how oncology is the single largest therapeutic area for pharmaceutical sales worldwide.
It’s that time of year again when we take stock of the advances the biopharma industry has made and look ahead to the evolving client requirements that will shape 2025 and beyond. Subodh Deshmukh, CEO of Aragen Bioscience discusses.
FUJIFILM Diosynth Biotechnologies has announced an expansion of its operations, a move that marks a pivotal moment in its journey as a leader in pharmaceuticals.
Since 2007, the contract laboratory Alphalyse A/S has developed and refined a new method of impurity analysis in biological pharmaceuticals based on mass spectrometry (MS).
Asahi Kasei Pharma has taken another step in its transformation into a global specialty pharmaceuticals company through a new licensing agreement with Chiome Bioscience for its humanised anti-CX3CR1 antibody.
Beckman Coulter Life Sciences, a company of Danaher Corporation, launches the Cydem VT Automated Clone Screening System, a high-throughput microbioreactor platform for automated top clone screening.
